Outcomes in the management of esophageal cancer

Journal of Surgical Oncology

Volumn 110, Issue 5, 2014, Pages 599-610

  Paul, Subroto ^a   Altorki, Nasser ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

esophageal cancer; esophagectomy; morbidity; mortality; neoadjuvant therapy; outcomes

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ANASTOMOSIS LEAKAGE; ANASTOMOSIS STENOSIS; BLEEDING; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHEMORADIOTHERAPY; CHYLOTHORAX; CONFERENCE PAPER; DIAPHRAGM HERNIA; EARLY CANCER; ENDOSCOPIC THERAPY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; HIGH VOLUME HOSPITAL; HUMAN; LOW VOLUME HOSPITAL; LUNG COMPLICATION; LYMPH NODE DISSECTION; META ANALYSIS (TOPIC); METASTASIS; MINIMALLY INVASIVE SURGERY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT LARYNGEAL NERVE INJURY; RESPIRATORY TRACT FISTULA; ROBOTIC SURGICAL PROCEDURE; STOMACH EMPTYING; SURGICAL MORTALITY; THROMBOEMBOLISM; ADJUVANT THERAPY; ESOPHAGEAL NEOPLASMS; POSTOPERATIVE COMPLICATION; TREATMENT OUTCOME;

ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; HUMANS; NEOADJUVANT THERAPY; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 84921814219     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23759     Document Type: Conference Paper

References (174)

1. Siegel R, Ma J, Zou Z, et al.,: Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Kuo EY, Chang Y, Wright CD:, Impact of hospital volume on clinical and economic outcomes for esophagectomy. Ann Thorac Surg 2001; 72: 1118-1124.
3. Begg CB, Cramer LD, Hoskins WJ, et al.,: Impact of hospital volume on operative mortality for major cancer surgery. Jama 1998; 280: 1747-1751.
4. Birkmeyer JD, Siewers AE, Finlayson EV, et al.,: Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346: 1128-1137.
5. Dimick JB, Cattaneo SM, Lipsett PA, et al.,: Hospital volume is related to clinical and economic outcomes of esophageal resection in Maryland. Ann Thorac Surg 72: 2001; 334-339, discussion 339-341
6. Kassis ES, Kosinski AS, Ross P Jr., et al,: Predictors of anastomotic l.: An analysis of the society of thoracic surgeons general thoracic database. Ann Thorac Surg 2013; 96: 1919-1926.
7. Devesa SS, Blot WJ, Fraumeni JF Jr., Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-2053.
8. Enzinger PC, Mayer RJ:, Esophageal cancer. N Engl J Med 2003; 349: 2241-2252.
9. Sjoquist KM, Burmeister BH, Smithers BM, et al.,: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: An updated meta-analysis. Lancet Oncol 2011; 12: 681-692
10. Gebski V, Burmeister B, Smithers BM, et al.,: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 2007; 8: 226-234.
11. Reames BN, Ghaferi AA, Birkmeyer JD, et al.,: Hospital volume and operative mortality in the modern era. Ann Surg 2013
12. Brusselaers N, Mattsson F, Lagergren J:, Hospital and surgeon volume in relation to long-term survival after oesophagectomy: Systematic review and meta-analysis. Gut 2014; 63: 1393-1400.
13. Bach PB, Cramer LD, Schrag D, et al.,: The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 2001; 345: 181-188.
14. Low DE, Kunz S, Schembre D, et al.,: Esophagectomy-it's not just about mortality anymore: Standardized perioperative clinical pathways improve outcomes in patients with esophageal cancer. J Gastrointest Surg 11: 2007; 1395-1402 discussion 1402
15. Altorki N, Kent M, Ferrara C, et al.,: Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 2002; 236: 177-183.
16. Altorki NK, Girardi L, Skinner DB:, En bloc esophagectomy improves survival for stage III esophageal cancer. J Thorac Cardiovasc Surg 114: 1997; 948-955 discussion 955-6
17. Rizk NP, Ishwaran H, Rice TW, et al.,: Optimum lymphadenectomy for esophageal cancer. Ann Surg 2010; 251: 46-50.
18. Lerut T, Moons J, Coosemans W, et al.,: Postoperative complications after transthoracic esophagectomy for cancer of the esophagus and gastroesophageal junction are correlated with early cancer recurrence: Role of systematic grading of complications using the modified Clavien classification. Ann Surg 2009; 250: 798-807.
19. Bartels H, Stein HJ, Siewert JR:, Preoperative risk analysis and postoperative mortality of oesophagectomy for resectable oesophageal cancer. Br J Surg 1998; 85: 840-844.
20. Schroder W, Bollschweiler E, Kossow C, et al.,: Preoperative risk analysis-a reliable predictor of postoperative outcome after transthoracic esophagectomy ? Langenbecks Arch Surg 2006; 391: 455-460.
21. Biere SS, van Berge Henegouwen MI, Maas KW, et al.,: Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: A multicentre, open-label, randomised controlled trial. Lancet 2012; 379: 1887-1892.
22. Dhungel B, Diggs BS, Hunter JG, et al.,: Patient and peri-operative predictors of morbidity and mortality after esophagectomy: American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP), 2005-2008. J Gastrointest Surg 2010; 14: 1492-1501.
23. Lapar DJ, Stukenborg GJ, Lau CL, et al.,: Differences in reported esophageal cancer resection outcomes between national clinical and administrative databases. J Thorac Cardiovasc Surg 2012; 144: 1152-1157.
24. Moller AM, Villebro N, Pedersen T, et al.,: Effect of preoperative smoking intervention on postoperative complications: A randomised clinical trial. Lancet 2002; 359: 114-117.
25. Tsui SL, Law S, Fok M, et al.,: Postoperative analgesia reduces mortality and morbidity after esophagectomy. Am J Surg 1997; 173: 472-478.
26. Paul S, Bueno R, Section VI:, Complications following esophagectomy: Early detection, treatment, and prevention. Semin Thorac Cardiovasc Surg 2003; 15: 210-215.
27. Griffin S, Desai J, Charlton M, et al.,: Factors influencing mortality and morbidity following oesophageal resection. Eur J Cardiothorac Surg 3: 1989; 419-423 discussion 424
28. Griffin SM, Shaw IH, Dresner SM:, Early complications after Ivor Lewis subtotal esophagectomy with two-field lymphadenectomy: Risk factors and management. J Am Coll Surg 2002; 194: 285-297.
29. Ferguson MK, Durkin AE:, Preoperative prediction of the risk of pulmonary complications after esophagectomy for cancer. J Thorac Cardiovasc Surg 2002; 123: 661-669.
30. Amar D, Roistacher N, Rusch VW, et al.,: Effects of diltiazem prophylaxis on the incidence and clinical outcome of atrial arrhythmias after thoracic surgery. J Thorac Cardiovasc Surg 2000; 120: 790-798.
31. Swanson SJ, Batirel HF, Bueno R, et al.,: Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg 72: 2001; 1918-1924 discussion 1924-5
32. Murthy SC, Law S, Whooley BP, et al.,: Atrial fibrillation after esophagectomy is a marker for postoperative morbidity and mortality. J Thorac Cardiovasc Surg 2003; 126: 1162-1167.
33. Jakobsen CJ, Bille S, Ahlburg P, et al.,: Perioperative metoprolol reduces the frequency of atrial fibrillation after thoracotomy for lung resection. J Cardiothorac Vasc Anesth 1997; 11: 746-751.
34. Fabian T, Rassias D, Daneshmand M, et al.,: Amiodarone for atrial fibrillation prophylaxis in patients undergoing esophagectomy. Chest 2004; 126: 800S.
35. Avendano CE, Flume PA, Silvestri GA, et al.,: Pulmonary complications after esophagectomy. Ann Thorac Surg 2002; 73: 922-926.
36. Atkins BZ, Fortes DL, Watkins KT:, Analysis of respiratory complications after minimally invasive esophagectomy: Preliminary observation of persistent aspiration risk. Dysphagia 2007; 22: 49-54.
37. Gillinov AM, Heitmiller RF:, Strategies to reduce pulmonary complications after transhiatal esophagectomy. Dis Esophagus 1998; 11: 43-47.
38. Clagett GP, Anderson FA Jr, Geerts W, et al.,: Prevention of venous thromboembolism. Chest 1998; 114: 531S-560S.
39. Lyman GH, Khorana AA, Falanga A, et al.,: American society of clinical oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.
40. Ramos R, Salem BI, De Pawlikowski MP, et al.,: The efficacy of pneumatic compression stockings in the prevention of pulmonary embolism after cardiac surgery. Chest 1996; 109: 82-85.
41. Orringer MB, Marshall B, Iannettoni MD:, Transhiatal esophagectomy: Clinical experience and refinements. Ann Surg 230: 1999; 392-400 discussion 400-3
42. Orringer MB, Marshall B, Stirling MC:, Transhiatal esophagectomy for benign and malignant disease. J Thorac Cardiovasc Surg 105: 1993; 265-276 discussion 276-7
43. Orringer MB, Marshall B, Iannettoni MD:, Eliminating the cervical esophagogastric anastomotic leak with a side-to-side stapled anastomosis. J Thorac Cardiovasc Surg 2000; 119: 277-288.
44. Raz DJ, Tedesco P, Herbella FA, et al.,: Side-to-side stapled intra-thoracic esophagogastric anastomosis reduces the incidence of leaks and stenosis. Dis Esophagus 2008; 21: 69-72.
45. Lam TC, Fok M, Cheng SW, et al.,: Anastomotic complications after esophagectomy for cancer. A comparison of neck and chest anastomoses. J Thorac Cardiovasc Surg 1992; 104: 395-400.
46. Martin LW, Swisher SG, Hofstetter W, et al.,: Intrathoracic leaks following esophagectomy are no longer associated with increased mortality. Ann Surg 242: 2005; 392-399 discussion 399-402
47. Shah DR, Martinez SR, Canter RJ, et al.,: Comparative morbidity and mortality from cervical or thoracic esophageal anastomoses. J Surg Oncol 2013; 108: 472-476.
48. Page RD, Khalil JF, Whyte RI, et al.,: Esophagogastrectomy via left thoracophrenotomy. Ann Thorac Surg 1990; 49: 763-766.
49. Mathisen DJ, Grillo HC, Wilkins EW Jr., et al.,: Carcinoma of the esophagus. Ann Thorac Surg 1988; 45: 137-143.
50. Urschel JD:, Esophagogastrostomy anastomotic leaks complicating esophagectomy: A review. Am J Surg 1995; 169: 634-640.
51. Martin LW, Hofstetter W, Swisher SG, et al.,: Management of intrathoracic leaks following esophagectomy. Adv Surg 2006; 40: 173-190.
52. Kauer WK, Stein HJ, Dittler HJ, et al.,: Stent implantation as a treatment option in patients with thoracic anastomotic leaks after esophagectomy. Surg Endosc 2008; 22: 50-53.
53. Maroney TP, Ring EJ, Gordon RL, et al.,: Role of interventional radiology in the management of major esophageal leaks. Radiology 1989; 170: 1055-1057.
54. Griffin SM, Lamb PJ, Dresner SM, et al.,: Diagnosis and management of a mediastinal leak following radical oesophagectomy. Br J Surg 2001; 88: 1346-1351.
55. David EA, Kim MP, Blackmon SH:, Esophageal salvage with removable covered self-expanding metal stents in the setting of intrathoracic esophageal leakage. Am J Surg 202: 2011; 796-801 discussion 801
56. Blackmon SH, Santora R, Schwarz P, et al.,: Utility of removable esophageal covered self-expanding metal stents for leak and fistula management. Ann Thorac Surg 89: 2010; 931-936 discussion 936-7
57. Schubert D, Scheidbach H, Kuhn R, et al.,: Endoscopic treatment of thoracic esophageal anastomotic leaks by using silicone-covered, self-expanding polyester stents. Gastrointest Endosc 2005; 61: 891-896.
58. Tuebergen D, Rijcken E, Mennigen R, et al.,: 2008; Treatment of thoracic esophageal anastomotic leaks and esophageal perforations with endoluminal stents: Efficacy and current limitations. J Gastrointest Surg
59. Hunerbein M, Stroszczynski C, Moesta KT, et al.,: Treatment of thoracic anastomotic leaks after esophagectomy with self-expanding plastic stents. Ann Surg 2004; 240: 801-807.
60. Korst RJ, Port JL, Lee PC, et al.,: Intrathoracic manifestations of cervical anastomotic leaks after transthoracic esophagectomy for carcinoma. Ann Thorac Surg 2005; 80: 1185-1190.
61. Lindenmann J, Matzi V, Porubsky C, et al.,: Self-expandable covered metal tracheal type stent for sealing cervical anastomotic leak after esophagectomy and gastric pull-up: Pitfalls and possibilities. Ann Thorac Surg 2008 85: 354-356.
62. Marty-Ane CH, Prudhome M, Fabre JM, et al.,: Tracheoesophagogastric anastomosis fistula: A rare complication of esophagectomy. Ann Thorac Surg 1995; 60: 690-693.
63. Matory YL, Burt M:, Esophagogastrectomy: Reoperation for complications. J Surg Oncol 1993; 54: 29-33.
64. Dewar L, Gelfand G, Finley RJ, et al.,: Factors affecting cervical anastomotic leak and stricture formation following esophagogastrectomy and gastric tube interposition. Am J Surg 1992; 163: 484-489.
65. Wong J, Cheung H, Lui R, et al.,: Esophagogastric anastomosis performed with a stapler: The occurrence of leakage and stricture. Surgery 1987; 101: 408-415.
66. Orringer MB, Bluett M, Deeb GM:, Aggressive treatment of chylothorax complicating transhiatal esophagectomy without thoracotomy. Surgery 1988; 104: 720-726.
67. Tuncozgur B, Savas MC, Isik AF, et al.,: Removal of metallic stent by using polyflex stent in esophago-colic anastomotic stricture. Ann Thorac Surg 2006; 82: 1913-1914.
68. Barthel JS, Kelley ST, Klapman JB:, Management of persistent gastroesophageal anastomotic strictures with removable self-expandable polyester silicon-covered (Polyflex) stents: An alternative to serial dilation. Gastrointest Endosc 2008; 67: 546-552.
69. Schipper PH, Cassivi SD, Deschamps C, et al.,: Locally recurrent esophageal carcinoma: When is re-resection indicated ? Ann Thorac Surg 80: 2005; 1001-1005 discussion 1005-6
70. Sharma V, Mahantshetty U, Dinshaw KA, et al.,: Palliation of advanced/recurrent esophageal carcinoma with high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2002; 52: 310-315.
71. Hulscher JB, ter Hofstede E, Kloek J, et al.,: Injury to the major airways during subtotal esophagectomy: Incidence, management, and sequelae. J Thorac Cardiovasc Surg 2000; 120: 1093-1096.
72. Bartels HE, Stein HJ, Siewert JR:, Tracheobronchial lesions following oesophagectomy: Prevalence, predisposing factors and outcome. Br J Surg 1998; 85: 403-406.
73. Sarkaria IS, Rizk NP, Finley DJ, et al.,: Combined thoracoscopic and laparoscopic robotic-assisted minimally invasive esophagectomy using a four-arm platform: Experience, technique and cautions during early procedure development. Eur J Cardiothorac Surg 2013; 43: e107-115.
74. Senkowski CK, Adams MT, Beck AN, et al.,: Minimally invasive esophagectomy: Early experience and outcomes. Am Surg 72: 2006; 677-683 discussion 683
75. Wu W, Zhu Q, Chen L, et al.,: Technical and early outcomes of Ivor Lewis minimally invasive oesophagectomy for gastric tube construction in the thoracic cavity. Interact Cardiovasc Thorac Surg 2014; 18: 86-91.
76. Pramesh CS, Sharma S, Saklani AP, et al.,: Broncho-gastric fistula complicating transthoracic esophagectomy. Dis Esophagus 2001; 14: 271-273.
77. Cerfolio RJ, Bryant AS, Yamamuro M:, Intercostal muscle flap to buttress the bronchus at risk and the thoracic esophageal-gastric anastomosis. Ann Thorac Surg 2005; 80: 1017-1020.
78. Bona D, Sarli D, Saino G, et al.,: Successful conservative management of benign gastro-bronchial fistula after intrathoracic esophagogastrostomy. Ann Thorac Surg 2007; 84: 1036-1038.
79. Li YD, Li MH, Han XW, et al.,: Gastrotracheal and gastrobronchial fistulas: Management with covered expandable metallic stents. J Vasc Interv Radiol 2006; 17: 1649-1656.
80. Paul S, Zellos L:, Management of a tracheo-gastric fistula after esophagectomy with a polyflex stent. J Broncho 1997; 14: 284-285.
81. Dugue L, Sauvanet A, Farges O, et al.,: Output of chyle as an indicator of treatment for chylothorax complicating oesophagectomy. Br J Surg 1998; 85: 1147-1149.
82. Staats BA, Ellefson RD, Budahn LL, et al.,: The lipoprotein profile of chylous and nonchylous pleural effusions. Mayo Clin Proc 1980; 55: 700-704.
83. Cerfolio RJ, Allen MS, Deschamps C, et al.,: Postoperative chylothorax. J Thorac Cardiovasc Surg 112: 1996; 1361-1365 discussion 1365-6
84. Bolger C, Walsh TN, Tanner WA, et al.,: Chylothorax after oesophagectomy. Br J Surg 1991; 78: 587-588.
85. Demos NJ, Kozel J, Scerbo JE:, Somatostatin in the treatment of chylothorax. Chest 2001; 119: 964-966.
86. Mikroulis D, Didilis V, Bitzikas G, et al.,: Octreotide in the treatment of chylothorax. Chest 121: 2002; 2079-2080 author reply 2080-1
87. Marts BC, Naunheim KS, Fiore AC, et al.,: Conservative versus surgical management of chylothorax. Am J Surg 164: 1992; 532-534 discussion 534-5
88. Tam PC, Fok M, Wong J:, Reexploration for complications after esophagectomy for cancer. J Thorac Cardiovasc Surg 1989; 98: 1122-1127.
89. Cope C, Salem R, Kaiser LR:, Management of chylothorax by percutaneous catheterization and embolization of the thoracic duct: Prospective trial. J Vasc Interv Radiol 1999; 10: 1248-1254.
90. Cope C:, Diagnosis and treatment of postoperative chyle leakage via percutaneous transabdominal catheterization of the cisterna chyli: A preliminary study. J Vasc Interv Radiol 1998; 9: 727-734.
91. Boffa DJ, Sands MJ, Rice TW, et al.,: A critical evaluation of a percutaneous diagnostic and treatment strategy for chylothorax after thoracic surgery. Eur J Cardiothorac Surg 2008; 33: 435-439.
92. Binkert CA, Yucel EK, Davison BD, et al.,: Percutaneous treatment of high-output chylothorax with embolization or needle disruption technique. J Vasc Interv Radiol 2005; 16: 1257-1262.
93. Orringer MB, Marshall B, Chang AC, et al.,: Two thousand transhiatal esophagectomies: Changing trends, lessons learned. Ann Surg 246: 2007; 363-372 discussion 372-4
94. Baba M, Aikou T, Natsugoe S, et al.,: Quality of life following esophagectomy with three-field lymphadenectomy for carcinoma, focusing on its relationship to vocal cord palsy. Dis Esophagus 1998; 11: 28-34.
95. Nishimaki T, Suzuki T, Suzuki S, et al.,: Outcomes of extended radical esophagectomy for thoracic esophageal cancer. J Am Coll Surg 1998; 186: 306-312.
96. Vallbohmer D, Holscher AH, Herbold T, et al.,: Diaphragmatic hernia after conventional or laparoscopic-assisted transthoracic esophagectomy. Ann Thorac Surg 2007; 84: 1847-1852.
97. van Sandick JW, Knegjens JL, van Lanschot JJ, et al.,: Diaphragmatic herniation following oesophagectomy. Br J Surg 1999; 86: 109-112.
98. Kent MS, Luketich JD, Tsai W, et al.,: Revisional surgery after esophagectomy: An analysis of 43 patients. Ann Thorac Surg 86: 2008; 975-983 discussion 967-74
99. Fok M, Cheng SW, Wong J:, Pyloroplasty versus no drainage in gastric replacement of the esophagus. Am J Surg 1991; 162: 447-452.
100. Burt M, Scott A, Williard WC, et al.,: Erythromycin stimulates gastric emptying after esophagectomy with gastric replacement: A randomized clinical trial. J Thorac Cardiovasc Surg 1996; 111: 649-654.
101. Khan OA, Manners J, Rengarajan A, et al.,: Does pyloroplasty following esophagectomy improve early clinical outcomes ? Interact Cardiovasc Thorac Surg 2007; 6: 247-250.
102. Lanuti M, de Delva PE, Wright CD, et al.,: Post-esophagectomy gastric outlet obstruction: role of pyloromyotomy and management with endoscopic pyloric dilatation. Eur J Cardiothorac Surg 2007; 31: 149-153.
103. Cheung HC, Siu KF, Wong J:, Is pyloroplasty necessary in esophageal replacement by stomach? A prospective, randomized controlled trial. Surgery 1987; 102: 19-24.
104. Donington JS:, Functional conduit disorders after esophagectomy. Thorac Surg Clin 2006; 16: 53-62.
105. Law S, Cheung MC, Fok M, et al.,: Pyloroplasty and pyloromyotomy in gastric replacement of the esophagus after esophagectomy: A randomized controlled trial. J Am Coll Surg 1997; 184: 630-636.
106. Urschel JD, Blewett CJ, Young JE, et al.,: Pyloric drainage (pyloroplasty) or no drainage in gastric reconstruction after esophagectomy: a meta-analysis of randomized controlled trials. Dig Surg 2002; 19: 160-164.
107. Greene CL, DeMeester SR, Worrell SG, et al.,: Alimentary satisfaction, gastrointestinal symptoms, and quality of life 10 or more years after esophagectomy with gastric pull-up. J Thorac Cardiovasc Surg 2014; 147: 909-914.
108. Darling GE:, Quality of life in patients with esophageal cancer. Thorac Surg Clin 2013; 23: 569-575.
109. Nafteux P, Durnez J, Moons J, et al.,: Assessing the relationships between health-related quality of life and postoperative length of hospital stay after oesophagectomy for cancer of the oesophagus and the gastro-oesophageal junction. Eur J Cardiothorac Surg 44: 2013; 525-533 discussion 533
110. Levy RM, Pennathur A, Luketich JD:, Randomized trial comparing minimally invasive esophagectomy and open esophagectomy: Early perioperative outcomes appear improved with a minimally invasive approach. Semin Thorac Cardiovasc Surg 2012; 24: 153-154.
111. Luketich JD, Pennathur A, Awais O, et al.,: Outcomes after minimally invasive esophagectomy: Review of over 1000 patients. Ann Surg 2012; 256: 95-103.
112. Pennathur A, Luketich JD:, Minimally invasive esophagectomy: Short-term outcomes appear comparable to open esophagectomy. Ann Surg 2012; 255: 206-207.
113. Tapias LF, Morse CR:, Minimally Invasive Ivor Lewis Esophagectomy: Description of a Learning Curve. J Am Coll Surg 2014; 218: 1130-1140.
114. Tapias LF, Muniappan A, Wright CD, et al.,: Short and long-term outcomes after esophagectomy for cancer in elderly patients. Ann Thorac Surg 2013; 95: 1741-1748.
115. Nguyen NT, Hinojosa MW, Smith BR, et al.,: Minimally invasive esophagectomy: Lessons learned from 104 operations. Ann Surg 2008; 248: 1081-1091.
116. Miao L, Chen H, Xiang J, et al.,: Ivor lewis esophagectomy for esophageal cancer: Review of over 1,300 patients. Chest 2014; 145: 58A.
117. Dhamija A, Hancock J, McCloskey B, et al.,: Minimally invasive oesophagectomy more expensive than open despite shorter length of stay. Eur J Cardiothorac Surg 2014; 45: 904-909.
118. Lee L, Li C, Robert N, et al.,: Economic impact of an enhanced recovery pathway for oesophagectomy. Br J Surg 2013; 100: 1326-1334.
119. Qumseya BJ, Panossian AM, Rizk C, et al.,: Survival in esophageal high-grade dysplasia/adenocarcinoma post endoscopic resection. Dig Liver Dis 2013; 45: 1028-1033.
120. Watson TJ:, Endoscopic resection for Barrett's esophagus with high-grade dysplasia or early esophageal adenocarcinoma. Semin Thorac Cardiovasc Surg 2008; 20: 310-319.
121. Davila ML, Hofstetter WL:, Endoscopic management of Barrett's esophagus with high-grade dysplasia and early-stage esophageal adenocarcinoma. Thorac Surg Clin 2013; 23: 479-489.
122. Lee L, Ronellenfitsch U, Hofstetter WL, et al.,: Predicting lymph node metastases in early esophageal adenocarcinoma using a simple scoring system. J Am Coll Surg 2013; 217: 191-199.
123. Altorki NK, Lee PC, Liss Y, et al.,: Multifocal neoplasia and nodal metastases in T1 esophageal carcinoma: Implications for endoscopic treatment. Ann Surg 2008; 247: 434-439.
124. Pech O, Bollschweiler E, Manner H, et al.,: Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Ann Surg 2011; 254: 67-72.
125. Pech O, Manner H, Ell C:, Endoscopic resection. Gastrointest Endosc Clin N Am 2011; 21: 81-94.
126. Manner H, Rabenstein T, Pech O, et al.,: Ablation of residual Barrett's epithelium after endoscopic resection: A randomized long-term follow-up study of argon plasma coagulation vs. surveillance (APE study). Endoscopy 2014; 46: 6-12.
127. Pech O, May A, Manner H, et al.,: Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus. Gastroenterology 146: 2014; 652-660 e1
128. Manner H, Pech O, Heldmann Y, et al.,: Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion. Clin Gastroenterol Hepatol 11: 2013; 630-635 quiz e45
129. Rice TW, Rusch VW, Ishwaran H, et al.,: Cancer of the esophagus and esophagogastric junction data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer 2010; 116: 3763-3773.
130. Rice TW, Blackstone EH, Rusch VW:, 7th edition of the AJCC cancer staging manual: Esophagus and esophagogastric junction. Ann Surg Oncol 2010; 17: 1721-1724.
131. Rice TW, Blackstone EH, Rusch VW:, A cancer staging primer: Esophagus and esophagogastric junction. J Thorac Cardiovasc Surg 2010; 139: 527-529.
132. Rice TW, Murthy SC, Mason DP, et al.,: Esophagectomy for clinical high-grade dysplasia. European Journal of Cardio-Thoracic Surgery 2011; 40: 113-119.
133. Lee PC, Mirza FM, Port JL, et al.,: Predictors of recurrence and disease-free survival in patients with completely resected esophageal carcinoma. J Thorac Cardiovasc Surg 2011; 141: 1196-1206.
134. Roth JA, Pass HI, Flanagan MM, et al.,: Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 1988; 96: 242-248.
135. Nygaard K, Hagen S, Hansen HS, et al.,: Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: A randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 16: 1992; 1104-1109 discussion 1110
136. Ancona E, Ruol A, Santi S, et al.,: Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: Final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001; 91: 2165-2174.
137. Schlag PM:, Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group. Arch Surg 1992; 127: 1446-1450.
138. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 2002; 359: 1727-1733.
139. Kelsen DP, Ginsberg R, Pajak TF, et al.,: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-1984.
140. Cunningham D, Allum WH, Stenning SP, et al.,: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
141. Kelsen DP, Winter KA, Gunderson LL, et al.,: Long-term results of RTOG trial 8911 (USA Intergroup 113): A random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007; 25: 3719-3725.
142. Allum WH, Stenning SP, Bancewicz J, et al.,: Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27: 5062-5067.
143. Boige V, Pignon J, Saint-Aubert B, et al.,: Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 2007; 25: 4510.
144. Ychou M, Boige V, Pignon JP, et al.,: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 1715; 29: -21.
145. Malthaner R, Fenlon D:, Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev 2003; CD001556.
146. Thirion PG, Michiels S, Le Maitre A, et al.,: Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal adenocarcinoma. J Clin Oncol 2007; 25: 4512.
147. Le Prise E, Etienne PL, Meunier B, et al.,: A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994; 73: 1779-84.
148. Apinop C, Puttisak P, Preecha N:, A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 1994; 41: 391-3913.
149. Walsh TN, Noonan N, Hollywood D, et al.,: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-467.
150. Law S, Kwong DLW, Tung HM:, Preoperative chemoradiation for squamous cell esophageal cancer: A prospective randomized trial (abstract). Can J Gastroenterology 1998; 12(Suppl B): 161.
151. Bosset JF, Gignoux M, Triboulet JP, et al.,: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337: 161-167.
152. Urba SG, Orringer MB, Turrisi A, et al.,: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19: 305-313.
153. Tepper J, Krasna MJ, Niedzwicki D:, Superiority of trimodality therapy to surgery alone in esophageal cancer: Results of CALGB 9781. J Clin Oncol 2006; 24: 181.
154. Burmeister BH, Smithers BM, Gebski V, et al.,: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial. Lancet Oncol 2005; 6: 659-668.
155. Lv J, Cao XF, Zhu B, et al.,: Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma. World J Gastroenterol 2010; 16: 1649-1654.
156. van de Gaast A, van Hagen P, Hulshof M, et al.,: Effect of preoperative concurrent radiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from a mutlicenter randomized phase III study. J Clin Oncol 2011; 28 (15 suppl): Abstract 4004
157. Mariette C, Seitz JF, Maillard B, et al.,: Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer; analysis of a randomized controlled phase III trial FFCD 9901. Proc Am Soc Clin Oncol 2010; 28: Abstract 4005
158. Ilson DH:, Cancer of the gastroesophageal junction: Combined modality therapy. Surg Oncol Clin N Am 2006; 15: 803-824.
159. Yoon HH, Gibson MK:, Combined-modality therapy for esophageal and gastroesophageal junction cancers. Curr Oncol Rep 2007; 9: 184-192.
160. Piraino A, Vita ML, Tessitore A, et al.,: Neoadjuvant therapy for esophageal cancer: Surgical considerations. Rays 2006; 31: 37-45.
161. McKian KP, Miller RC, Cassivi SD, et al.,: Curing patients with locally advanced esophageal cancer: An update on multimodality therapy. Dis Esophagus 2006; 19: 448-453.
162. Shinoda M, Hatooka S, Mori S, et al.,: Clinical aspects of multimodality therapy for resectable locoregional esophageal cancer. Ann Thorac Cardiovasc Surg 2006; 12: 234-241.
163. van Hagen P, Hulshof MC, van Lanschot JJ, et al.,: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084.
164. Urschel JD, Vasan H:, A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185: 538-543.
165. Fiorica F, Di Bona D, Schepis F, et al.,: Preoperative chemoradiotherapy for oesophageal cancer: A systematic review and meta-analysis. Gut 2004; 53: 925-930.
166. Greer SE, Goodney PP, Sutton JE, et al.,: Neoadjuvant chemoradiotherapy for esophageal carcinoma: A meta-analysis. Surgery 2005; 137: 172-177.
167. Malthaner RA, Wong RK, Rumble RB, et al.,: Neoadjuvant or adjuvant therapy for resectable esophageal cancer: A systematic review and meta-analysis. BMC Med 2004; 2: 35.
168. Stahl M, Walz MK, Stuschke M, et al.,: Preoperative chemotherapy (CTX) versus preoperative chemoradiotherapy (CRTZ) in locally advanced esophagogastric adenocarcinomas: First results of a randomized phase III trial. J Clin Oncol 2007; 25: 4511.
169. Burmeister BH, Thomas JM, Burmeister EA, et al.,: Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer 47: 354-60.
170. Bonner JA, Harari PM, Giralt J, et al.,: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
171. Ruhstaller T, Pless M, Dietrich D, et al.,: Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: A prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol 2011; 29: 626-631.
172. Reed C, Decker P, Schefter T, et al.,: A phase II study of neoadjuvant therapy with cisplatin, docetaxel, panitumumab plus radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051). J Clin Oncol 2012; 30: (suppl; abstr 4062).
173. De Vita F, Orditura M, Martinelli E, et al.,: A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. Br J Cancer 2011; 104: 427-432.
174. Kordes S, Richel D, Henegouwen vB, et al,: Mul.: Panitumumab with chemoradiation followed by surgery for patients with operable esophageal cancer (PACT-study). J Clin Oncol 2012; 30: (suppl; abstr 4094).